Quantum Genomics Appoints Benoît Gueugnon as Vice President of Finance
PARIS and NEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC, OTCQX - QNNTF), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure, today announced the appointment of Benoît Gueugnon as Vice-President Finance. He will succeed Marc Karako who is leaving the Company.
Benoît graduated from the Normandy Business School and holds a Masters II Degree in Audit & Corporate Finance. Benoît brings strong financial experience to Quantum Genomics senior management team, having previously served as Senior Financial Auditor at KPMG Paris. He joined Quantum Genomics in 2018 as Group Financial Controller and worked closely with Marc Karako.
Jean-Philippe Milon, Chief Executive Officer of Quantum Genomics said: « I thank Benoît, who since beginning with Quantum Genomics in 2018, has demonstrated enthusiasm and his efficiency, particularly in driving the execution of Quantum Genomic’s recently signed partnership with Biolab. I am very pleased to promote him to this strategic position. His energy and skillset are strong assets for our Company. »
Benoît Gueugnon commented: “I express my gratitude to Jean-Philippe, the Quantum Genomics management team and its board of directors for this opportunity. I look forward to continue supporting Quantum Genomics in this new capacity, and at this exciting time for the Company in which it is launching a Phase III clinical trial in difficult-to-treat and resistant hypertension, and looks to sign new partnerships in 2020.”
- Picture available on request -
About Quantum Genomics
Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).
Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF). For more information, please visit , or follow us on and .
| Contacts | |
| Quantum Genomics | |
| Jean-Philippe Milon | Benoît Gueugnon |
| CEO | CFO |
| So Bang (Europe) | |
| Nathalie Boumendil | Samuel Beaupain |
| Financial Communications | Media Relations and Scientific Communications |
| +33 (0)6 85 82 41 95 | | +33 (0)6 88 48 48 02 | |
| LifeSci (USA) | |
| Dan Ferry | Mike Tattory |
| Financial Communications | Media Relations and Scientific Communications |
| +1 (617) 535-7746 | | +1 (609) 802-6265 | |
